Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25400077 | 0.91 | TDP1 (0.39) | TDP1NT5EP2RY12P2RY2P2RY4 | |
| SCHEMBL19861796 | 0.91 | TDP1 (0.39) | TDP1NT5EP2RY12P2RY2P2RY4 | |
| SCHEMBL25400083 | 0.91 | TDP1 (0.39) | TDP1NT5EP2RY12P2RY2P2RY4 | |
| SCHEMBL25400092 | 0.89 | TDP1 (0.39) | TDP1NT5EP2RY12P2RY2P2RY4 | |
| SCHEMBL16993619 | 0.89 | TDP1 (0.39) | TDP1NT5EP2RY12P2RY2P2RY4 | |
| SCHEMBL25400099 | 0.89 | TDP1 (0.39) | TDP1NT5EP2RY12P2RY2P2RY4 | |
| SCHEMBL16991644 | 0.89 | TDP1 (0.39) | TDP1NT5EP2RY12P2RY2P2RY4 | |
| SCHEMBL1097256 | 0.87 | TK1 (0.39) | — | |
| SCHEMBL14929374 | 0.87 | TDP1 (0.41) | TDP1NT5EP2RY12P2RY2P2RY4 | |
| SCHEMBL14946311 | 0.87 | TDP1 (0.41) | TDP1NT5EP2RY12P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2024-11-14 | — | — | US | disclosed |
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | SANOFI (FR) | 2024-02-13 | — | — | US | disclosed |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-11-24 | — | — | US | disclosed |
| EP-4025582-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | SANOFI (FR) | 2022-07-13 | — | — | EP | disclosed |
| CN-114728999-A | Oligonucleotides containing nucleotide analogs | 赛诺菲 | 2022-07-08 | — | — | CN | disclosed |
| US-20210115075-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI (FR) | 2021-04-22 | — | — | US | disclosed |
| CN-112105625-A | Nucleotide precursors, nucleotide analogs, and oligomeric compounds containing the same | 赛诺菲 | 2020-12-18 | — | — | CN | disclosed |
| EP-1015469-B2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2015-11-18 | — | — | EP | disclosed |
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-11-04 | — | — | US | disclosed |
| US-20100267018-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-10-21 | — | — | US | disclosed |
| US-7572582-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2009-08-11 | — | — | US | disclosed |
| US-7034133-B2 | Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance | EXIQON A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | QIAGEN GMBH (DE) | 2005-12-29 | — | — | US | disclosed |
| EP-1557424-A1 | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| EP-1015469-B1 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2005-04-13 | — | — | EP | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | RNMT, RRM2B, RRM2 | TDP1 481/4885NT5E 252/4885P2RY12 2348/4885 |
| US-20210115075-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, RRM2B, RRM2 | TDP1 481/4885NT5E 252/4885P2RY12 2348/4885 |
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | TDP1 125/4885NT5E 168/4885P2RY12 2109/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | TDP1 1779/4885NT5E 972/4885P2RY12 2613/4885 |
| US-20100267018-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | TDP1 171/4885NT5E 48/4885P2RY12 1858/4885 |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | POLRMT, POLM, POLN | TDP1 363/4885NT5E 59/4885P2RY12 1569/4885 |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, NSUN2, ADAR | TDP1 375/4885NT5E 127/4885P2RY12 2347/4885 |
| US-20220372063-A1 | OLIGONUCLEOTIDES CONTAINING NUCLEOTIDE ANALOGS | DCLRE1B, UPF1, IGF2BP1 | TDP1 353/4885NT5E 171/4885P2RY12 4378/4885 |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | TDP1 171/4885NT5E 48/4885P2RY12 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.